253 related articles for article (PubMed ID: 21852131)
21. Assessment of the Embryonic Stem Cell Test and application and use in the pharmaceutical industry.
Paquette JA; Kumpf SW; Streck RD; Thomson JJ; Chapin RE; Stedman DB
Birth Defects Res B Dev Reprod Toxicol; 2008 Apr; 83(2):104-11. PubMed ID: 18361453
[TBL] [Abstract][Full Text] [Related]
22. Metabolites in safety testing.
Robison TW; Jacobs A
Bioanalysis; 2009 Oct; 1(7):1193-200. PubMed ID: 21083045
[TBL] [Abstract][Full Text] [Related]
23. Follow-on drugs: how far should chemists look?
Giordanetto F; Boström J; Tyrchan C
Drug Discov Today; 2011 Aug; 16(15-16):722-32. PubMed ID: 21658467
[TBL] [Abstract][Full Text] [Related]
24. A medicinal chemistry perspective on structure-based drug design and development.
Maddaford SP
Methods Mol Biol; 2012; 841():351-81. PubMed ID: 22222460
[TBL] [Abstract][Full Text] [Related]
25. Reducing attrition in drug development: smart loading preclinical safety assessment.
Roberts RA; Kavanagh SL; Mellor HR; Pollard CE; Robinson S; Platz SJ
Drug Discov Today; 2014 Mar; 19(3):341-7. PubMed ID: 24269835
[TBL] [Abstract][Full Text] [Related]
26. Evaluations of organ system development in juvenile toxicology testing.
Robinson K
Reprod Toxicol; 2008 Sep; 26(1):51-3. PubMed ID: 18595655
[TBL] [Abstract][Full Text] [Related]
27. Biomedical imaging in the safety evaluation of new drugs.
Wang YX; Yan SX
Lab Anim; 2008 Oct; 42(4):433-41. PubMed ID: 18782821
[TBL] [Abstract][Full Text] [Related]
28. High-content micronucleus assay in genotoxicity profiling: initial-stage development and some applications in the investigative/lead-finding studies in drug discovery.
Mondal MS; Gabriels J; McGinnis C; Magnifico M; Marsilje TH; Urban L; Collis A; Bojanic D; Biller SA; Frieauff W; Martus HJ; Suter W; Bentley P
Toxicol Sci; 2010 Nov; 118(1):71-85. PubMed ID: 20631060
[TBL] [Abstract][Full Text] [Related]
29. Overview of the nonclinical quality and toxicology testing for recombinant biopharmaceuticals produced in mammalian cells.
Lebrec H; Narayanan P; Nims R
J Appl Toxicol; 2010 Jul; 30(5):387-96. PubMed ID: 20589744
[TBL] [Abstract][Full Text] [Related]
30. Development of a large-scale chemogenomics database to improve drug candidate selection and to understand mechanisms of chemical toxicity and action.
Ganter B; Tugendreich S; Pearson CI; Ayanoglu E; Baumhueter S; Bostian KA; Brady L; Browne LJ; Calvin JT; Day GJ; Breckenridge N; Dunlea S; Eynon BP; Furness LM; Ferng J; Fielden MR; Fujimoto SY; Gong L; Hu C; Idury R; Judo MS; Kolaja KL; Lee MD; McSorley C; Minor JM; Nair RV; Natsoulis G; Nguyen P; Nicholson SM; Pham H; Roter AH; Sun D; Tan S; Thode S; Tolley AM; Vladimirova A; Yang J; Zhou Z; Jarnagin K
J Biotechnol; 2005 Sep; 119(3):219-44. PubMed ID: 16005536
[TBL] [Abstract][Full Text] [Related]
31. Use of surface charges from DFT calculations to predict intestinal absorption.
Jones R; Connolly PC; Klamt A; Diedenhofen M
J Chem Inf Model; 2005; 45(5):1337-42. PubMed ID: 16180910
[TBL] [Abstract][Full Text] [Related]
32. Systematic approaches to toxicology in the zebrafish.
Peterson RT; Macrae CA
Annu Rev Pharmacol Toxicol; 2012; 52():433-53. PubMed ID: 22017682
[TBL] [Abstract][Full Text] [Related]
33. Forging synergies in drug discovery.
Nat Chem Biol; 2008 Feb; 4(2):83. PubMed ID: 18202672
[No Abstract] [Full Text] [Related]
34. Safety assessment of drug metabolites: implications of regulatory guidance and potential application of genetically engineered mouse models that express human P450s.
Powley MW; Frederick CB; Sistare FD; DeGeorge JJ
Chem Res Toxicol; 2009 Feb; 22(2):257-62. PubMed ID: 19170595
[TBL] [Abstract][Full Text] [Related]
35. Optimising the design of preliminary toxicity studies for pharmaceutical safety testing in the dog.
Smith D; Combes R; Depelchin O; Jacobsen SD; Hack R; Luft J; Lammens L; von Landenberg F; Phillips B; Pfister R; Rabemampianina Y; Sparrow S; Stark C; Stephan-Gueldner M
Regul Toxicol Pharmacol; 2005 Mar; 41(2):95-101. PubMed ID: 15698532
[TBL] [Abstract][Full Text] [Related]
36. Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates.
Palucki M; Higgins JD; Kwong E; Templeton AC
J Med Chem; 2010 Aug; 53(16):5897-905. PubMed ID: 20527889
[No Abstract] [Full Text] [Related]
37. Exploratory toxicology as an integrated part of drug discovery. Part II: Screening strategies.
Hornberg JJ; Laursen M; Brenden N; Persson M; Thougaard AV; Toft DB; Mow T
Drug Discov Today; 2014 Aug; 19(8):1137-44. PubMed ID: 24374152
[TBL] [Abstract][Full Text] [Related]
38. Improved preclinical safety assessment using micro-BAL devices: the potential impact on human discovery and drug attrition.
Giri S; Bader A
Drug Discov Today; 2011 May; 16(9-10):382-97. PubMed ID: 21354326
[TBL] [Abstract][Full Text] [Related]
39. What have we learned from pre-clinical juvenile toxicity studies?
Bailey GP; Mariën D
Reprod Toxicol; 2009 Sep; 28(2):226-9. PubMed ID: 19446432
[TBL] [Abstract][Full Text] [Related]
40. Incidence and nature of testicular toxicity findings in pharmaceutical development.
Sasaki JC; Chapin RE; Hall DG; Breslin W; Moffit J; Saldutti L; Enright B; Seger M; Jarvi K; Hixon M; Mitchard T; Kim JH
Birth Defects Res B Dev Reprod Toxicol; 2011 Dec; 92(6):511-25. PubMed ID: 22162370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
